Practical management of behavioral problems in mucopolysaccharidoses disorders

Mol Genet Metab. 2017 Dec:122S:35-40. doi: 10.1016/j.ymgme.2017.09.010. Epub 2017 Sep 27.

Abstract

The mucopolysaccharidosis (MPS) disorders are caused by deficiencies of specific lysosomal enzymes, resulting in progressive glycosaminoglycan (GAG) accumulation in cells and tissues throughout the body. Excessive GAG storage can lead to a variety of somatic manifestations as well as primary and secondary neurological symptoms. Behavioral problems (like hyperactivity, attention difficulties, and severe frustration) and sleeping problems are typical primary neurological symptoms of MPS caused by GAG accumulation in neurons, and are frequently observed in patients with MPS I, II, III, and VII. As these problems often place a significant burden on the family, proper management is important. This review summarizes current insights into behavioral and sleeping problems in MPS disorders and the most optimal management approaches, as presented and discussed during a meeting of an international group of experts with extensive experience in managing and treating MPS.

Keywords: Behavior; Child behavior disorders; Lysosomal storage diseases; Mental disorders; Mucopolysaccharidoses.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Behavior Therapy / methods*
  • Brain / cytology
  • Brain / drug effects
  • Brain / enzymology
  • Brain / metabolism
  • Central Nervous System Depressants / pharmacology
  • Central Nervous System Depressants / therapeutic use*
  • Child
  • Child Behavior / drug effects*
  • Child, Preschool
  • Congresses as Topic
  • Dyssomnias / etiology
  • Dyssomnias / psychology
  • Dyssomnias / therapy*
  • Glycosaminoglycans / metabolism
  • Glycosaminoglycans / toxicity
  • Humans
  • Mucopolysaccharidoses / complications
  • Mucopolysaccharidoses / pathology
  • Mucopolysaccharidoses / psychology
  • Mucopolysaccharidoses / therapy*
  • Treatment Outcome

Substances

  • Central Nervous System Depressants
  • Glycosaminoglycans